miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance– An emphasis on the interaction of signaling pathways

• Published in: Pathology, research and practice Vol. 243; p. 154363
• Main Authors: Doghish, Ahmed S., Abulsoud, Ahmed I., Elshaer, Shereen Saeid, Abdelmaksoud, Nourhan M., Zaki, Mohamed Bakr, El-Mahdy, Hesham A., Ismail, Ahmed, Fathi, Doaa, Elsakka, Elsayed G.E.
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-03-2023
• Subjects: Biogenesis; Biomarkers; Chronic lymphocytic leukemia (CLL); Drug resistance; Drug Resistance, Neoplasm - genetics; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; MicroRNAs (miRs, miRNAs); MicroRNAs - genetics; Oncogenic miRNAs; Signal Transduction; Tumor suppressor (TS) miRNAs; VEGFRs; CLL; Caspase 9; TGFBR; Wnt/β-catenin; PTEN; Chronic lymphocytic leukemia (CLL); Drug resistance; ncRNAs; NF-κB; PI3K; CCND1; shRNA; XPO5; DGCR8; AKT1; CDKN; Biogenesis; CSCs; RAG1; Hh; PIAS3; STATs; TPM1; GAB1; MAPK; FOXP1; BCR; ILs; TCL1; SMO; Notch1; Oncogenic miRNAs; BTK; Tumor suppressor (TS) miRNAs; TP53; ERK; CD20; ABC; XIAP; MicroRNAs (miRs, miRNAs); miRs; HIF-1; Tcf-3; TLR; VHL; JAKs; MCL1; RISC; FZD3; TGFB1; PTCH1; STAT3; UTRs; Egr-1; AGO; SOCS; PLCγ2; TME; SMAD7; 7mG; FZD; Mcl-1; LSCs; NZB; BCL2; PDCD4; FOXO3a; TLRs; BCL2L2; TS
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154363

Chronic lymphocytic leukemia (CLL) accounts for the vast majority of cases of leukemia. Patients of advanced age are more likely to develop the condition, which has a highly varied clinical course. Consideration of illness features and preceding treatment sequence, as well as patient preferences and comorbidities, is necessary for selecting the appropriate treatment for the appropriate patient. Therefore, there is an urgent need for novel biomarkers with high sensitivity and specificity to detect CLL early, monitor CLL patients, select the treatment responders, and reduce ineffective treatment, unwanted side effects, and unnecessary expenses. In both homeostasis and illness, microRNAs (miRNAs/miRs) play a vital role as master regulators of gene expression and, by extension, protein expression. MiRNAs typically reduce the stability of mRNAs, including those encoding genes involved in tumorigenesis processes as cell cycle regulation, inflammation, stress response, angiogenesis, differentiation, apoptosis, and invasion. Due to their unique properties, miRNAs are rapidly being exploited as accurate biomarkers for illness detection, and medicines based on miRNA targets are finding widespread application in clinical practice. Accordingly, the current review serves as a quick primer on CLL and the biogenesis of miRNAs. In addition to providing a brief overview of the miRNAs whose function in the progression of CLL has been established by recent in vitro or in vivo research through articulating the influence of these miRNAs on a wide variety of cellular functions, including increased proliferative potential; support for angiogenesis; cell cycle aberration; evasion of apoptosis; promotion of metastasis; and reduced sensitivity to specific treatments.